Clinical trials: Nipah Virus Infection
Nipah Virus Infection
A Phase 1 Study to Evaluate Safety & Immunogenicity of RVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects
A Phase 1 Study to Evaluate the Safety and Immunogenicity of rVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects
- Trial name
- NCT05178901
- Testing
- PHV02
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Public Health Vaccines LLC
Nipah Virus Infection
Safety and Immunogenicity of a Nipah Virus Vaccine
A first-in-human, phase 1 trial is to be conducted in a healthy adult population in the US to assess the safety and immunogenicity of three ascending Nipah vaccine (HeV-sG-V; Hendra virus soluble glycoprotein vaccine) dosages.
- Trial name
- NCT04199169
- Testing
- HeV-sG-V
- Where
- United States
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Auro Vaccines LLC
Nipah Virus Infection
Study to Evaluate Safety and Immunogenicity of a Prime-Boost Regimen of rVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects
The goal of this clinical trial is to test the safety and immunogenicity of PHV02 live, attenuated recombinant vesicular stomatitis virus vaccine expressing the Nipah Virus glycoprotein in healthy adult subjects.
- Trial name
- NCT06221813
- Testing
- PHV02, Lactated Ringer's
- Where
- 3 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Public Health Vaccines LLC